Wellcome Trust Scientific Conferences, Wellcome Trust Conference Centre
29 September - 2 October 2011
Pharmacogenomics and Personalised Medicine is becoming more prominent and will have a major impact on the way medicines are prescribed to patients and, as a consequence, how they are developed in industry. This meeting will focus on the opportunities presented by the growing contribution of genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how this research can benefit the individual. The meeting will provide in depth discussion on diverse areas including the use of next generation sequencing technologies to identify common and rare variants determining the response to drugs; the interface of pharmacogenomics and complex disease, including cancer; understanding and managing serious adverse drug reactions; personalising medicine. We will bring together senior and junior investigators, postdoctoral and postgraduate researchers, medical, regulatory and ethical experts in a range of disciplines to share new research and experience, and to explore the potential of working together in new international and interdisciplinary research areas for the benefit of individual patients. The conference programme and unique venue provides a superb forum for interaction among the delegates. We encourage the submission of high quality abstracts for consideration as posters and/or platform presentations.
Please note: This meeting will follow the UK Pharmacogenetics and Stratified Medicine Network 2011 meeting (28 September). Conference Topics:
Stratified medicine
Public health pharmacogenetics & addictions
Next generation sequencing
Serious adverse reactions
The interface of common diseases and pharmacogenetics
Cancer pharmacogenomics
|
|
|
Invited Speakers:
|
|
Scientific organising committee:
Hiltrud Brauch, Institute of Clinical Pharmacology (IKP) Stuttgart, Germany
Panos Deloukas, Wellcome Trust Sanger Institute, UK
Deanna Kroetz, University of California, USA
Munir Pirmohamed, University of Liverpool, UK Speakers:
Lon Cardon, GlaxoSmithKline, USA
Ann Daly, Newcastle University, UK
Michael Hayden, Centre for Molecular Medicine and Therapeutics, USA
Leroy Hood, Insititute for Sytems Biology, USA
Ewan Khoury, Centers for Disease Control and Prevention, USA
Ultan McDermott, Wellcome Trust Sanger Institute, UK
Steve Scherer, Baylor College of Medicine, USA
Matthias Schwab, Dr. Margarete Fischer-Bosch-Institute, Germany
Rachel Tyndele, CAMH and University of Toronto, Canada
Axel Ulrich, Max Planck Institute of Biochemistry, Germany
|
|